Background-Long term oral corticosteroid treatment is a cause of myopathyof the skeletal muscles. (Thorax 1993;48:979-984) 
on the respiratory muscles is uncertain. Respiratory muscle function and fatigue in sternomastoid muscle were investigated in a group of patients with chronic severe asthma who were taking oral corticosteroids. The results were compared with those from a group of patients with chronic airflow limitation who were not taking oral steroids. Methods-Twelve patients with chronic severe asthma, taking a mean daily dosage of 8 mg of prednisolone for a mean (SD) of 16-8 (9.1) years, were compared with patients with chronic airflow limitation and individually matched for sex, age, and severity of airflow limitation. Lung function tests, maximal mouth pressures, and quadriceps and sternomastoid muscle strength were measured. The sternomastoid muscle was fatigued by maximal headlift exercise to 70% of initial headlift force and the endurance time noted. Sternomastoid fatigue was assessed by twitch maximum relaxation rate (TMRR) measured in the fresh state and for 30 minutes after exercise. Results-There was no significant difference between the control group and the corticosteroid group for maximal mouth pressures, fresh state TMRR, and quadriceps and sternomastoid strength. The control group had a significantly longer mean (SD) endurance time than the corticosteroid group (121 (47) s v 86 (24) s), and also had significantly less slowing and faster recovery of the TMRR after exercise. The slowing and recovery of the TMRR in the corticosteroid group, however, was similar to that previously reported for normal subjects. Conclusion-Respiratory muscle weakness does not occur more often in patients taking oral corticosteroids. The corticosteroid group was more prone to fatigue than the control group, but was similar to normal subjects. This suggests that chronic airflow limitation may produce a traning effect on the respiratory muscles that might be attenuated by long term oral corticosteroid treatment. (Thorax 1993; 48:979-984) Despite the widespread use of potent topical inhaled corticosteroids for the treatment of asthma, some patients with chronic severe asthma remain dependent on long term oral corticosteroid treatment to control their symptoms. These patients are at risk from the well known systemic side effects of oral corticosteroids, which include adrenal suppression, osteoporosis, impaired carbohydrate metabolism, truncal obesity, dermal thinning, and myopathy. Corticosteroid induced myopathy has been described mainly in the proximal skeletal muscles'-3 and is usually related to long term treatment. Myopathy of the peripheral muscles has been described in asthmatic patients given long term oral corticosteroid treatment4 and also in patients given short periods of treatment with intravenous steroids.56
Little is known about the effects of long term oral corticosteroid treatment on the function of the respiratory muscles. If corticosteroid induced myopathy also involves the respiratory muscles, this could predispose to weakness and fatigue of these muscles and subsequent respiratory failure. To date, studies have not shown obvious respiratory muscle weakness in patients with respiratory disease given steroids.478 It is not known, however, if long term corticosteroid treatment makes the respiratory muscles prone to fatigue.
We have previously described a simple and sensitive test to detect fatigue in an accessory muscle of respiration-namely, the slowing of the sternomastoid muscle twitch maximum relaxation rate (TMRR).9 The TMRR of certain muscles in animals is slower in muscles with myopathy induced by corticosteroids.'°I 1 Therefore, the TMRR of the sternomastoid muscle may serve as an indicator of corticosteroid induced myopathy in the respiratory muscles in humans.
We have investigated respiratory muscle function and stemomastoid muscle fatigue with the sternomastoid TMRR technique in a group of patients with chronic severe asthma requiring long term oral corticosteroid treatment.
Patients and methods

PATIENTS
We studied 12 patients with chronic severe asthma requiring long term oral corticosteroid treatment. All had a well documented history of variability of lung function responsive to oral corticosteroid treatment, but could not be weaned off their oral corticosteroids despite high dose inhaled corticosteroid medication. All had been taking oral corticosteroids for at least two years before the study. Patients were studied in a stable clinical condition on their minimum maintenance oral corticosteroid dose plus their usual medications, which included high dose inhaled corticosteroids (> 1500 pg/day beclomethasone), inhaled fJ2 agonists, ipratropium bromide and, in four patients, oral theophyllines.
It was possible to individually match these patients with a control group of patients with chronic airflow limitation who had never taken regular oral steroids. piece was attached to a rigid perspex tube 30 cm in length and 3 cm internal diameter. The tube had a 1-5 mm diameter leak hole 15 cm down its length to prevent closure of the glottis during respiratory manoeuvres. The pressure generated within the tube was measured with a Medex vascular pressure transducer (Medex Inc, Rossendale, UK) attached to the end of the tube. This system has been validated for measuring respiratory pressures and has a precision of + 2%.'4 Maximum inspiratory pressure (Pimax) was measured from residual volume and maximum expiratory pressure (PEmax) was measured at total lung capacity with the patients' palms pressing against their cheeks to prevent any contribution from the buccal musculature. The maximal pressure sustained for at least one second was recorded and the best of four attempts taken. Reference values previously established by our laboratory with this technique were used. 1 '
STERNOMASTOID MUSCLE STRENGTH AND ENDURANCE
Sternomastoid muscle strength was assessed by measuring the maximum voluntary headlift force. The patients lay on a couch with their head and shoulders resting on a pillow at an angle of 30-45 degrees. Patients were asked to lift their foreheads a few centimetres from the resting position and to push as hard as possible against a pad attached to a load cell (Dyanometer UF-2, Ormed, UK) secured above them. The headlift force thus obtained was recorded on a chart recorder and calculated in Newtons (N). The best of four attempts was taken. Seventy per cent of the maximum headlift force was calculated and marked on the chart recorder. The patients were then exercised by performing repeated maximal headlifts against the fixed pad for two seconds followed by two seconds rest (giving a tension/time index of 50%). This exercise was continued until each subject could not achieve 70% of their initial maximum headlift force on three consecutive attempts despite active encouragement. The time taken to this point was recorded as the endurance time.
STERNOMASTOID FATIGUE
Sternomastoid fatigue was assessed from the sternomastoid twitch maximum relaxation rate. Full details of this technique have been described previously.9 Briefly, patients were studied lying at an angle of 30-45 degrees. The right sternomastoid muscle was stimulated with two electrodes (3M Red Dot ECG electrode), one placed on the sternum and the other placed over the insertion of the accessory nerve into the body of the muscle. The anterior force vector generated by the muscle contraction was measured with a load cell (Dyanometer UF-2, Ormed, UK) attached to a curved perspex head pressed firmly on to the medial (sternal) tendon of the muscle. The load cell was in turn attached to a custom designed rigid metal frame that allowed adjustments in several directions to simplify ideal placement.
The muscle was electrically stimulated with a unidirectional square wave impulse of 50,s. Twitches were recorded with a UV light sensitive chart recorder running at 100 mm/s (Micromovements, UK). Initially, maximal stimulation voltage was determined by measuring the twitch force response to increasing voltages and was taken as the lowest voltage that gave a maximal twitch response (usually 50-80 V). Stimulation voltage for each patient was set at 10 V above the maximal voltage (to ensure supramaximal stimulation) and all twitches performed at 1 Hz with the breath held at end tidal expiration. Up to eight twitches could be performed during each breathhold. At least 24 twitches were measured in the fresh state. After the endurance exercise protocol, twitches were recorded at 1, 2X5, 5, 7-5, 10, 15, and 30 minutes, with at least eight twitches on each occasion.
All recorded twitches were analysed by hand. The TMRR was taken as the slope of the tangent drawn against the steepest part of the relaxation curve (usually the initial 10-50% of the curve) normalised for the peak twitch force, and expressed as % force loss/10 ms. Any twitch that did not have a smooth relaxation curve was rejected. At least six acceptable twitches were used to calculate the mean TMRR for each period after exercise.
PERIPHERAL MUSCLE STRENGTH
Peripheral muscle strength was assessed from the quadriceps muscle with a standard quadriceps chair.'6 The leg was held in passive flexion with an ankle strap attached to a custom built strain gauge. Patients were asked to make maximal extension movements at the knee against the ankle strap. The force produced was recorded on a chart recorder. The best of four attempts was used and force was calculated in Newtons (N). Predicted values for quadriceps strength were calculated from equations based on age, sex and height, The mean maximal mouth pressures for both the matched corticosteroid group and the control group were similar and within the normal range for adults as established previously in our laboratory (table 2).'5 In the matched corticosteroid group, however, two patients had a PImax or PEmax below the normal range for their sex as did five patients in the control group. Based on Fisher's exact test, there was no significant difference in the prevalence of patients with respiratory pressures below the normal range between the two groups. Of the five patients who had abnormal respiratory pressures in the control group, three had also had quadriceps weakness. In the 18 additional patients on corticosteroids, three were below the normal range for either Pimax or PEmax.
The mean sternomastoid muscle TMRRs in the matched corticosteroid and control groups were similar (table 2) and were within the normal range established in this laboratory from 32 normal subjects (mean (SD) (1-91), range 5-8-13-44% force loss/l10 ms).
The mean (SD) endurance time of headlift exercise was significantly longer in the control (fig 1) . In the control group, two subjects showed little change or acceleration of the TMRR after exercise. These two subjects could have accounted for the significant differences between the two groups. If these two controls, together with the two corticosteroid patients with whom they were matched, were excluded from the analysis, however, the mean percentage slowing and rate of recovery of the TMRR between the two groups still remained significantly different.
The fall and recovery of the TMRR was similar between the smaller group of patients taking corticosteroids and the additional 18 patients taking corticosteroids (fig 2) .
There was no correlation between any of the indices of muscle function with the dose of steroids, or with the duration of use of steroids, or with the product of these two variables.
, that the sternomastoid muscle in corticogroup compared with the matched cortico-steroid dependent asthmatic patients fatigues steroid group (121(47)s v 86(24)s, p < 0-05). more easily and takes longer to recover from Despite less exercise, however, the mean fatigue than in patients with equivalent severpercentage slowing from fresh state TMRR ity of airflow obstruction but not taking oral was significantly greater in the matched corti-corticosteroids.
The prolonged slowing of the TMRR in the asthmatic group shows a major advantage of the TMRR over the more commonly used indicator of the fatiguing process, the maximum relaxation rate (MRR; measured after tetanic stimulation or maximum voluntary contractions).'6" After fatiguing exercise, slowing of the stemomastoid TMRR lasts for longer than the MRR, and seems to follow the time course of low frequency fatigue. 9 Also, the sternomastoid muscle TMRR slows before the loss of force generating capacity, and the degree of slowing and rate of recovery of the TMRR is related to the preceding load. '8 30 ings could relate to differences in the two disTime after exercise (min) eases we have studied. The load on the age slowing and recovery offresh state TMRR after exercise in the respiratory muscles in chronic airflow limitaoup (0, n = 12) and previously studied normal subjects tion is fairly constant, whereas it may be intermittent in asthma. All our asthmatic subjects, however, were studied in a stable condition), it is possible that sternomastoid muscle tion and had severe airflow limitation in the function in the corticosteroid group is actu-stable state. Therefore, they would have a ally normal. The decreased slowing and more similar chronic load to that of the patients rapid recovery of the TMRR shown by our with chronic airflow limitation together with control group may well be due to a training intermittent exacerbations, so should have effect on the accessory muscles of respiration in these patients because of the constant use of these muscles to breathe (supranormal). If this was the case, however, the corticosteroid group, which was closely matched for respiratory impairment, should also have exhibited a training effect on the sternomastoid muscle.
A possible explanation as to why no training effect was seen in the corticosteroid dependent asthmatic patients could be that corticosteroids do actually produce a myopathy of the respiratory muscles, but the constant use of such muscles in these breathless patients keeps the function of the muscles at normal levels. The protective effect of regular exercise in preventing corticosteroid induced myopathy in other muscles has been well described in both animal models' 22 and human subjects.2324 Therefore, regular use of the respiratory muscles in corticosteroid treated patients may prevent them from becoming myopathic. Alternatively, steroids may attenuate the training effects of chronic airflow obstruction and stop the muscles from becoming supranormal. We did not examine the quadriceps or the sternomastoids of our asthmatic patients histologically, so we cannot be sure if any had steroid induced myopathy. Only one of our asthmatic patients had evidence of peripheral muscle weakness, whereas four patients in the control group had weak quadriceps muscles, so it seems unlikely that many patients treated with corticosteroids had a significant peripheral myopathy.
Gandevia and colleagues have also found increased endurance in the respiratory muscles of patients with chronic airflow limitation and asthma. 
